Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
ATP-152 by Boehringer Ingelheim International for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
ATP-152 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to...